The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects.
Non-hodgkin Lymphoma,B Cell
DRUG: CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
DLT, The number and severity of dose-limiting toxicity (DLT) events, Within 28 Days After BRL-201 Infusion|AEs, The total number, incidence, and severity of AEs, Up to 24 Months After BRL-201 Infusion|RP2D, The recommended phase 2 dose, Within 28 Days After BRL-201 Infusion
This is a multi-center, single-arm, open-label clinical study, and the sample size is set to 12-18 subjects. Based on the "3 + 3" dose escalation design principle, subjects will be divided into 3 groups from low dose to high dose in sequence (Group A; Group B; Group C. Additional subjects will be enrolled into the RP2D group to ensure that 6-9 efficacy-evaluable subjects are available in the RP2D group before entering the phase II study.